PASG Passage BIO Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PASG

Price (delayed)

$1.35

Market cap

$75.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.86

Enterprise value

$79.64M

Passage Bio, has the mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with ...

Highlights
The EPS has grown by 26% YoY and by 9% from the previous quarter
The net income is up by 25% year-on-year and by 9% since the previous quarter
The quick ratio has decreased by 32% YoY but it has increased by 4.3% QoQ
The equity has contracted by 45% YoY and by 12% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.passagebio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of PASG
Market
Shares outstanding
55.6M
Market cap
$75.06M
Enterprise value
$79.64M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.67
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$102.06M
EBITDA
-$98.34M
Free cash flow
-$78.41M
Per share
EPS
-$1.86
Free cash flow per share
-$1.43
Book value per share
$2.03
Revenue per share
$0
TBVPS
$2.75
Balance sheet
Total assets
$150.55M
Total liabilities
$39.26M
Debt
$26.29M
Equity
$111.28M
Working capital
$101.62M
Liquidity
Debt to equity
0.24
Current ratio
7.22
Quick ratio
6.99
Net debt/EBITDA
-0.05
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-56.2%
Return on equity
-73.1%
Return on invested capital
-63.7%
Return on capital employed
-76%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PASG stock price

How has the Passage BIO stock price performed over time
Intraday
0.75%
1 week
2.27%
1 month
0%
1 year
37.47%
YTD
33.66%
QTD
0%

Financial performance

How have Passage BIO's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$102.06M
Net income
-$102.06M
Gross margin
N/A
Net margin
N/A
The net income is up by 25% year-on-year and by 9% since the previous quarter
The operating income is up by 25% year-on-year and by 9% since the previous quarter

Growth

What is Passage BIO's growth rate over time

Valuation

What is Passage BIO stock price valuation
P/E
N/A
P/B
0.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 26% YoY and by 9% from the previous quarter
The stock's price to book (P/B) is 65% more than its last 4 quarters average of 0.4 but 49% less than its 5-year quarterly average of 1.3
The equity has contracted by 45% YoY and by 12% from the previous quarter

Efficiency

How efficient is Passage BIO business performance
The company's return on equity fell by 28% YoY and by 5% QoQ
PASG's return on assets is down by 18% year-on-year and by 2.6% since the previous quarter
The ROIC has contracted by 2.1% from the previous quarter

Dividends

What is PASG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PASG.

Financial health

How did Passage BIO financials performed over time
Passage BIO's total assets has decreased by 38% YoY and by 11% from the previous quarter
Passage BIO's current ratio has decreased by 33% YoY but it has increased by 5% from the previous quarter
The debt is 76% less than the equity
The debt to equity has soared by 85% YoY and by 14% from the previous quarter
The equity has contracted by 45% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.